GEN Stock Price Fell 38.09%: Why It Happened

By Amit Chowdhry ● March 4, 2021
  • The stock price of Genesis Healthcare, Inc. (NYSE: GEN) fell by 38.09% yesterday. This is why it happened.

The stock price of Genesis Healthcare, Inc. (NYSE: GEN) fell by 38.09% yesterday and it is down over 19% pre-market as of 6:49 AM ET. Investors were responding to the company announcing a three-part strategic restructuring plan to strengthen the Company’s liquidity position and capital structure as it charts a path to recovery:

1.) Genesis agreed to terminate its master lease covering 51 facilities leased from affiliates of Welltower and transition operations to new operators. And in return, Genesis will receive approximately $86 million, which it will use to repay a portion of its debt obligations to Welltower. Plus Genesis will receive approximately an additional $170 million in debt reduction from Welltower upon the occurrence of certain conditions, including the transition of the 51 facilities.

2.) Genesis entered into a definitive agreement with ReGen Healthcare, LLC (“ReGen Healthcare”) for a capital infusion of $50 million.

3.) Genesis will voluntarily delist its Class A common stock (the “Common Stock”) from the New York Stock Exchange and deregister its Common Stock under the Securities Exchange Act of 1934 (the “Exchange Act”).

Transition out of 51 facilities leased from Welltower

Currently, Genesis leases 246 skilled nursing and assisted/senior living facilities from third parties, including public and private real estate investment trusts (“REITs”). And one of the company’s largest landlords Welltower will re-tenant and/or sell the 51 facilities it leases to Genesis affiliates, in 9 states. Plus Genesis will continue to operate the facilities until appropriate approvals from state regulators are completed. The transitions are expected to occur over the next several months.

Genesis is also indebted to Welltower in an approximate amount of $423 million. And in return for its agreement to terminate its master lease with Welltower, upon the transition of the operations of all 51 facilities, Genesis will receive approximately $86 million – which it will use to repay a portion of its debt obligations to Welltower. In addition, the company will receive approximately $170 million in additional debt reductions from Welltower upon the satisfaction of certain conditions, including the transitioning of all 51 facilities. As a result, in total, Genesis expects to reduce its debt outstanding to Welltower by approximately $256 million and extend maturity to January 1, 2024. Welltower will also permit certain collateral to be released and utilized as collateral for new debt.

Before the COVID-19 pandemic, these 51 facilities generated on a combined basis approximate annual net revenue of $640 million. And this transaction will result in the reduction of $79 million in annual cash lease expenses. Plus Welltower will also receive equity in the company, increasing its stake in Genesis on a fully-diluted basis from approximately 6% to up to approximately 15%.

Investment Agreement with ReGen Healthcare

Genesis has also secured a $50 million debt investment from ReGen Healthcare, LLC. And this debt investment converts into equity representing a 25% ownership interest in the company’s subsidiaries on a fully-diluted basis, contingent upon both the receipt of all required regulatory approvals and the reduction of indebtedness owed by Genesis to Welltower.

ReGen Healthcare also has the option to make an additional debt investment of $25 million exercisable no later than March 31, 2021 and to be funded by April 15, 2021. And if made, this debt investment will convert into equity simultaneously with the conversion of the initial debt investment into equity, resulting in a 33.3% ownership interest in the company’s subsidiaries on a fully-diluted basis. Plus at the closing of the second investment, ReGen Healthcare would be issued a warrant, exercisable for equity, which, together with the two debt investments, would represent an ownership interest of approximately 43% of the Company’s subsidiaries on a fully-diluted basis.

ReGen Healthcare – together with its affiliates and its principals – has a track record of successfully creating and turning around companies that improve both healthcare delivery and insurance processes for health plans, their members, and their provider partners. And one of these affiliates Pinta Capital Partners has invested widely in innovative services for the chronically ill and applied new practices in services to one of the neediest, frailest and most vulnerable populations.

As part of the agreement, two Genesis Board Members John F. DePodesta and Terry Rappuhn have relinquished their current positions and ReGen Healthcare has appointed David Harrington and John Randazzo, effective immediately. In addition, Harrington has been appointed Chairman of the Board.

Harrington brings 35 years of industry experience in critical areas of healthcare delivery management to the Board. He has held executive positions at AETNA, UnitedHealthcare, Columbia/HCA and Physician Quality Care. As CEO of American Imaging Management (AIM) from 2001 to 2008, Harrington turned around this radiology management business, increasing its net worth from negative $19 million to over $350 million. In August 2007, AIM was sold to WellPoint for $307 million. And since 2009, when Harrington established DASH Business Group, he has advised and developed many healthcare companies in the senior care space. Harrington is one of the founding principals of Pinta Partners and in that role is passionate about rethinking the delivery of health care to the chronically ill.

Randazzo has spent more than 35 years in the health care and technology fields and brings rich experience in operational excellence, corporate finance and entrepreneurship. Currently, he is Executive Chairman of Waters Edge Dermatology, one of the largest dermatology practices in the country, and Executive Chairman of Sentry Data Systems, a provider of pharmacy technology solutions to hospitals. Randazzo previously co-founded and led one of the nation’s largest independent urgent care companies, FastMed. He has held executive positions at Value Oncology Science, Women’s Health Connecticut Inc. and CIGNA. Randazzo has served as a senior advisor to global private equity firm, Warburg Pincus, for over 20 years.

Delisting from the NYSE and Deregistration under the Exchange Act

In connection with the investment by ReGen Healthcare, Genesis agreed and intends to voluntarily delist its Common Stock from the New York Stock Exchange. And the company has agreed and intends to deregister its Common Stock under the Exchange Act and suspend its public reporting obligations.

The company is intending to file a Form 25 with the Securities and Exchange Commission on or about March 15, 2021 in order to delist from the New York Stock Exchange. And the company anticipates that the last day of trading on New York Stock Exchange will be on or about March 25, 2021.

On or about March 25, 2021, Genesis intends to file a Form 15 with the SEC, at which time the company anticipates that its obligations to file periodic reports under the Exchange Act, including annual, quarterly and current reports on Form 10-K, Form 10-Q and Form 8-K, respectively, will be suspended, and that all requirements associated with being an Exchange Act-registered company, including the requirement to file current and periodic reports, will terminate 90 days thereafter.

Following the deregistration, Genesis anticipates that its Common Stock will be quoted on the OTC Pink Open Market (the “Pink Sheets”), a centralized electronic quotation service for over-the-counter securities, so long as market makers demonstrate an interest in trading in the Common Stock. However, the Company can give no assurance that trading in its Common Stock will continue on the Pink Sheets or any other securities exchange or quotation medium.

Genesis expects to file its 2020 Form 10-K by March 16, 2021, but it will not distribute a Q4 2020 earnings release or host a conference call.


“The severity of the pandemic dramatically impacted patient admissions, revenues and costs, compounding the pressures of our long-term, lease-related debt obligations. These restructuring transactions improve the financial and operational stability of the Company significantly and build on the encouraging signs we are seeing as COVID-19 case rates continue to materially decline and residents, patients and staff are vaccinated.”

– Chief Executive Officer Robert Fish

Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.